Last reviewed · How we verify

rAd-IFN — Competitive Intelligence Brief

rAd-IFN (rAd-IFN) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: oncolytic virus. Area: Oncology.

phase 3 oncolytic virus Oncology Biologic Live · refreshed every 30 min

Target snapshot

rAd-IFN (rAd-IFN) — Ferring Ventures Limited. rAd-IFN is a recombinant adenovirus vector-based gene therapy that expresses interferon-alpha.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
rAd-IFN TARGET rAd-IFN Ferring Ventures Limited phase 3 oncolytic virus
rAd-p53 gene rAd-p53 gene Shenzhen SiBiono GeneTech Co.,Ltd marketed Gene therapy; oncolytic virus p53 tumor suppressor gene
AdV-tk AdV-tk Candel Therapeutics, Inc. phase 3 Oncolytic virus Tumor cells (HSV-tk prodrug activation pathway)
Virulizin® Virulizin® Aptose Biosciences Inc. phase 3 Oncolytic virus

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (oncolytic virus class)

  1. Ferring Ventures Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). rAd-IFN — Competitive Intelligence Brief. https://druglandscape.com/ci/rad-ifn. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: